Aurora was founded to address a defining challenge in rare disease: while more than 350 million people worldwide are affected, most lack treatments that target their specific genetic mutations. Traditional development models cannot scale to thousands of rare variants, leaving the vast majority of patients without options. Aurora exists to change this reality by transforming personalized gene editing from isolated, heroic efforts into a systematic, scalable approach capable of reaching patients with any disease variant. Our team brings together leaders in gene editing, rare-disease medicine, regulatory science, and therapeutic development who have already demonstrated what personalized gene editing can achieve. They are building the first platform designed for many-at-a-time development, driven by their shared passion to realize the potential of personalized gene editing for millions of patients with rare diseases.
Is this your company?
Something looks off?